Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.83 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | ABL2 | P42684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29752007 | 1.00 | EGFR (1.00) | EGFRERBB2ABL1SRCABL2 | |
| SCHEMBL29444159 | 0.91 | ERBB2 (1.00) | EGFRERBB2SRC | |
| SCHEMBL22590126 | 0.91 | ERBB2 (1.00) | EGFRERBB2SRC | |
| SCHEMBL29444165 | 0.91 | ERBB2 (1.00) | EGFRERBB2SRC | |
| SCHEMBL22598672 | 0.89 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL29752032 | 0.89 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL22598687 | 0.87 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL29751938 | 0.87 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL22598674 | 0.86 | EGFR (1.00) | EGFRERBB2ABL1SRCABL2 | |
| SCHEMBL29751985 | 0.86 | EGFR (1.00) | EGFRERBB2ABL1SRCABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-21 | — | — | US | disclosed |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-21 | — | — | US | disclosed |
| US-20200354343-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-12 | — | — | US | disclosed |
| US-20200354343-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-12 | — | — | US | disclosed |
| WO-2020219904-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354343-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885ABL1 5/4885 |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885ABL1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.